Dateline City:
KENILWORTH, N.J.
In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from three studies investigating the use of
KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy,
in combination with three other immunotherapies epacadostat, IMLYGICTM
(talimogene laherparepvec), and ipilimumab in patients with advanced
melanoma.
Language:
English
Contact:
MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestors:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more